¢Æ¢Æ¢Æ¢Æ º¸°Çº¹ÁöºÎ ¾à¹°´ë»çÀ¯Àüü¿¬±¸¼¾ÅÍ ¢Æ¢Æ¢Æ¢Æ
HOME < ¿¬±¸¼º°ú <
ƯÇã½ÇÀû
³âµµº° ºÐ·ù:
±¹³»Æ¯Çã
ÇØ¿ÜƯÇã
Ä«Å×°í¸®¼±ÅÃ
¸ðµÎº¸±â
2006-International
2006-Domestic
2005-International
2005-Domestic
2004-International
2004-Domestic
2003-International
2003-Domestic
2007-International
2007-Domestic
¿ÀÁö¿¬, ±èµ¿Çö, ½ÅÀç±¹, Á¶¿ë¼ø, Çã´Ù¿µ
°áÇÙÀÇ ´ë»çü ¹ÙÀÌ¿À¸¶Ä¿ (±¹³»Æ¯Çã )
Ãâ¿ø 10-2021-0126566 / 2021.09.24 [LINK ]
¼¼ö±æ, ±èäÀº, ¹ÚÇÏ¿µ, ±è¹Î¿µ, ±èµ¿Çö, ½ÅÀç±¹
Ç×°áÇÙÁ¦ Ä¡·á È¿°ú ÁõÁø¿ë Á¶¼º¹° (±¹³»Æ¯Çã )
Ãâ¿ø 10-2020-0007334 / 2020.01.20 [LINK ]
½ÅÀç±¹, ±èÈ£¼÷, Â÷Àº¿µ, Á¤ÇýÀº
¾à¹° ºÎÀÛ¿ë°ú °ü·ÃµÈ ´ë¸³À¯ÀüÀÚ ¹× ÀÌÀÇ °ËÃâ ¹æ¹ý (±¹³»Æ¯Çã )
µî·Ï 10-2050637-0000 / 2019.11.25 [LINK ]
ÃÖÈ£Áø, ÀÌÀç¿ø, ÀÌâ°ï, Çϴϳª, ¼¼ö±æ, À̼±¹Ì, À̼º¹Î
N-acylhydrazonderivate für einen selektiven t-zell-inhibitor und ein arzneimittel gegen anti-lymphoid-malignität (ÇØ¿ÜƯÇã )
À¯·´Æ¯Çã Ãâ¿ø EP2890677B1 / 2017.11.15 [LINK ]
½ÅÀç±¹, ±èÈ£¼÷, Â÷Àº¿µ, Á¤ÇýÀº
¾à¹° ºÎÀÛ¿ë°ú °ü·ÃµÈ ´ë¸³À¯ÀüÀÚ ¹× ÀÌÀÇ °ËÃâ ¹æ¹ý (±¹³»Æ¯Çã )
Ãâ¿ø 10-2017-0132224 / 2017.10.12 [LINK ]
ÃÖÈ£Áø, ÀÌÀç¿ø, ÀÌâ°ï, Çϴϳª, ¼¼ö±æ, À̼±¹Ì, À̼º¹Î
N-acylhydrazone derivatives for selective T cell inhibitors and anti-lymphocytic malignancies (ÇØ¿ÜƯÇã )
ÀϺ»Æ¯Çã Ãâ¿ø JP6139682B2 / 2017.05.31 [LINK ]
½ÅÀç±¹, ÀÌ»ó¼·, ±èÀº¿µ, Á¤ÇýÀº, ¹ÚÁ¤¼ø, ±èÁ¾·ü, ¼ÁöÀº
Çѱ¹Àο¡¼ CYP2D6 À¯ÀüÇüÀ» Æ÷ÇÔÇÏ´Â ¾à¹°¹ÝÀÀ À¯ÀüÀÚµéÀÇ À¯ÀüÇü ºÐ¼®À» À§ÇÑ Ç¥ÁØ À¯ÀüÀÚ ºÒ¸êÈ ¼¼Æ÷ÁÖ (±¹³»Æ¯Çã )
µî·Ï 10-1593750-0000 / 2016.02.03 [LINK ]
ÃÖÈ£Áø, ÀÌÀç¿ø, ÀÌâ°ï, Çϴϳª, ¼¼ö±æ, À̼±¹Ì, À̼º¹Î
N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug (ÇØ¿ÜƯÇã )
¹Ì±¹Æ¯Çã Ãâ¿ø US9447083B2 / 2016.09.20 [LINK ]
ÃÖÈ£Áø, ÀÌÀç¿ø, ÀÌâ°ï, Çϴϳª, ¼¼ö±æ, À̼±¹Ì, À̼º¹Î
¼±ÅÃÀû £Ô ¼¼Æ÷ ¾ïÁ¦Á¦ ¹× Ç×-¸²ÇÁÁ¾¾ç ¾à¹°·Î¼ À¯¿ëÇÑ £Î-¾Æ½ÇÇÏÀ̵å¶óÁ¸ À¯µµÃ¼ (±¹³»Æ¯Çã )
µî·Ï 10-1561987-0000 / 2015.10.14 [LINK ]
À̼öÁØ, ÀÌ»ó¼·, ½ÅÀç±¹, ±è¿ì¿µ
Çѱ¹ÀÎÀÇ SULT1A1 ¹× SULT1A2 À¯ÀüÀÚÀÇ À¯ÀüÀû ´ÙÇü¼ºÀ» ºÐ¼®ÇÏ´Â ¹æ¹ý (±¹³»Æ¯Çã )
µî·Ï 10-1555294-0000 / 2015.09.17 [LINK ]
1
2
3
4
5
6
7
Á¦¸ñ
ÀúÀÚ¸í
Áö¿ø°úÁ¦